Chemotherapy News and Research

Latest Chemotherapy News and Research

Unitedhealth says it will test lump sum payments for some cancer care, reports earnings

Health insurer UnitedHealth said Tuesday that it will test a new way payment method for cancer doctors. The program pays doctors a lump sum payment for providing care during an entire course of care for the disease instead of how it's done now with a fee for each service a doctor provides.

21 Oct 2010

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

NYU Langone Medical Center is pleased to announce that it has established The Smilow Comprehensive Prostate Cancer Center with a $5 million gift from Joel E. Smilow, a member of the Board of Trustees at NYU Langone Medical Center and New York University. The Smilow Center is dedicated to providing comprehensive, state-of-the-art personalized care for men with prostate cancer as well as educating men and their families about the disease and the wide range of treatment options available today.

21 Oct 2010

A new way to pay for chemotherapy

Kaiser Health News staff writer Julie Appleby reports: "One of the nation's largest health insurers said today it is testing a new way to pay for some cancer treatments, aiming to identify the best medicines - and limit profits doctors make by dispensing in-office chemotherapy drugs" (Appleby, 10/20).

21 Oct 2010

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

Genzyme Corporation announced results today from its CLASSIC I phase 3 trial comparing Clolar® (clofarabine) in combination with the chemotherapy agent cytarabine (ara-c) to cytarabine plus placebo in relapsed-refractory adult acute myeloid leukemia (AML).

21 Oct 2010

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

Genentech, a member of the Roche Group today announced the U.S. Food and Drug Administration (FDA) has approved Herceptin (trastuzumab) in combination with chemotherapy (cisplatin plus either capecitabine or 5-fluorouracil [5-FU]) for HER2-positive metastatic (cancer that has spread) cancer of the stomach or gastroesophageal junction, in men and women who have not received prior medicines for their metastatic disease.

21 Oct 2010

First Edition: October 20, 2010

Kaiser Health News staff writer Julie Appleby reports One of the nation's largest health insurers said today it is testing a new way to pay for some cancer treatments, aiming to identify the best medicines and limit profits doctors make by dispensing in-office chemotherapy drugs.

20 Oct 2010

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Curcumin, the major component in the spice turmeric, when combined with the drug Cisplatin enhances the chemotherapy's suppression of head and neck cancer cell growth, researchers with UCLA's Jonsson Cancer Center have found.

20 Oct 2010

Mirna announces USPTO allows claims to therapeutic application of let-7 miRNA

Mirna Therapeutics, Inc. announced today that the USPTO has allowed claims related to the therapeutic application of let-7 in the regulation of oncogenes. The claims derive from a patent application that was submitted by Yale University and exclusively licensed to Mirna related to the pioneering work of Dr. Frank Slack, Professor of Molecular, Cellular & Developmental Biology at Yale University in New Haven, CT.

20 Oct 2010

MD Anderson treats lung cancer with pencil beam scanning proton therapy

Pencil beam scanning technology, an even more advanced and targeted form of radiation treatment known as proton therapy, is now being used to treat patients with lung cancer at The University of Texas MD Anderson Cancer Center.

20 Oct 2010

BCAN holds regional Bladder Cancer Patient Forum at New York Academy of Medicine

Bladder cancer is the fifth most commonly diagnosed cancer in the United States, yet most people know nothing about it. To help enhance the public's understanding of the risks and signs of bladder cancer and the importance of early detection and treatment options, the Bladder Cancer Advocacy Network (BCAN) will hold its regional Bladder Cancer Patient Forum "Understanding Bladder Cancer" on Saturday, October 23, 2010, in New York City at the New York Academy of Medicine.

20 Oct 2010

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended September 30, 2010. Total revenues for the third quarter of 2010 were $1.94 billion, up 8 percent compared to total revenues of $1.80 billion for the third quarter of 2009. Net income for the third quarter of 2010 was $704.9 million, or $0.83 per diluted share, compared to net income for the third quarter of 2009 of $673.0 million, or $0.72 per diluted share.

20 Oct 2010

Researchers to study effectiveness of gamma-tocotrienol on prostate cancer cells

Survival rates of the world's most common cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumour regrowth. Queensland University of Technology (QUT) prostate cancer researchers are leading the fight against a disease which kills 3000 Australian men a year.

20 Oct 2010

Agendia establishes contract with Humana for coverage of MammaPrint breast cancer recurrence test

Agendia, a world leader in molecular cancer diagnostics, announced today that it has established a contract with leading insurance provider Humana to reimburse for the company's MammaPrint test. Agendia's contract with Humana expands the coverage for MammaPrint by more than 17 million lives. In November 2009, Palmetto GBA, California's Part B Medicare administrator, established coding guidelines for MammaPrint, allowing healthcare providers from across the United States to submit claims for the test.

19 Oct 2010

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Rexahn Pharmaceuticals, Inc. a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of new preclinical data on the development of 3-aryl-1-isoquinolinamines in the European Journal & Medicinal Chemistry.

19 Oct 2010

Increased colorectal cancer screening in pre-Medicare population can reduce program costs

Investment in screening programs that target the pre-Medicare population, individuals aged between 50 and 64, is needed to reduce the costs of colorectal cancer in the Medicare program, according to the results of a new study, "Cost-Savings to Medicare from Increased Colorectal Cancer Screening in the Pre-Medicare Population," unveiled today at the American College of Gastroenterology's (ACG) 75th Annual Scientific meeting in San Antonio, Texas.

19 Oct 2010

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of Phase II clinical trial of the company's investigative immunomodulatory agent, CYT107 (rhIL-7), in combination with two potent antiretroviral drugs represented by the integrase inhibitor raltegravir (ISENTRESS- Merck & Co.) and the CCR5 inhibitor, maraviroc (SELZENTRY- ViiV Healthcare).

19 Oct 2010

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

Amgen will review the results from TREAT (the Trial to Reduce Cardiovascular Events with Aranesp® Therapy) and will discuss how these results inform the appropriate use of erythropoiesis-stimulating agents (ESAs) for chronic renal failure (CRF) patients at today's meeting of the Food and Drug Administration's (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC).

19 Oct 2010

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

New data on odanacatib, an investigational cathepsin-K (Cat-K) inhibitor in development for the treatment of osteoporosis in postmenopausal women, were presented at the 32nd Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Toronto, Canada.

19 Oct 2010

Researchers identify new mechanism that could help develop effective chemotherapy drug

Information on proteins is critical for understanding how cells function in health and disease. But while regular proteins are easy to extract and study, it is far more difficult to gather information about membrane proteins, which are responsible for exchanging elements essential to our health, like copper, between a cell and its surrounding tissues.

19 Oct 2010

Medifocus receives two patents to expand IP portfolio

Medifocus, Inc. is pleased to announce that it has recently received notice of allowances for two additional international patents to expand its extensive Intellectual Properties (IP) portfolio in addition to the patents Medifocus has exclusively licensed from the Massachusetts Institute of Technology (MIT).

19 Oct 2010

Chemotherapy News and Research

Latest Chemotherapy News and Research

Unitedhealth says it will test lump sum payments for some cancer care, reports earnings

NYU Langone Medical Center announces establishment of Smilow Comprehensive Prostate Cancer Center

A new way to pay for chemotherapy

Genzyme reports results of Clolar combination Phase 3 trial in adult AML

FDA approves Herceptin with chemotherapy for HER2-positive metastatic cancer

First Edition: October 20, 2010

Turmeric component enhances chemotherapy's suppression of head and neck cancer

Mirna announces USPTO allows claims to therapeutic application of let-7 miRNA

MD Anderson treats lung cancer with pencil beam scanning proton therapy

BCAN holds regional Bladder Cancer Patient Forum at New York Academy of Medicine

Gilead Sciences third quarter total revenues increase 8% to $1.94 billion

Researchers to study effectiveness of gamma-tocotrienol on prostate cancer cells

Agendia establishes contract with Humana for coverage of MammaPrint breast cancer recurrence test

Rexahn announces publication of 3-aryl-1-isoquinolinamines preclinical data

Increased colorectal cancer screening in pre-Medicare population can reduce program costs

Cytheris initiates ORVACS Phase II clinical trial to study HIV infection

Amgen to review study results of ESA in chronic renal failure patients with FDA and CRDAC

New data on Merck’s odanacatib for osteoporosis in postmenopausal women presented at 32nd ASBMR

Researchers identify new mechanism that could help develop effective chemotherapy drug

Medifocus receives two patents to expand IP portfolio

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research - Second Edition eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in